[go: up one dir, main page]

WO2008130630A3 - Forme polymorphique de l'hydrochlorure de rimonabant et ses procédés de fabrication - Google Patents

Forme polymorphique de l'hydrochlorure de rimonabant et ses procédés de fabrication Download PDF

Info

Publication number
WO2008130630A3
WO2008130630A3 PCT/US2008/005022 US2008005022W WO2008130630A3 WO 2008130630 A3 WO2008130630 A3 WO 2008130630A3 US 2008005022 W US2008005022 W US 2008005022W WO 2008130630 A3 WO2008130630 A3 WO 2008130630A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
polymorphic form
rimonabant hydrochloride
rimonabant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/005022
Other languages
English (en)
Other versions
WO2008130630A4 (fr
WO2008130630A2 (fr
Inventor
Eli Lancry
Marina Kalujny
Claude Singer
Sigalit Levi
Michal Rafilovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Publication of WO2008130630A2 publication Critical patent/WO2008130630A2/fr
Publication of WO2008130630A3 publication Critical patent/WO2008130630A3/fr
Publication of WO2008130630A4 publication Critical patent/WO2008130630A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a trait à une forme cristalline de l'hydrochlorure de rimonabant, à ses procédés de fabrication et à des compositions pharmaceutiques contenant ladite forme cristalline de l'hydrochlorure de rimonabant.
PCT/US2008/005022 2007-04-16 2008-04-16 Forme polymorphique de l'hydrochlorure de rimonabant et ses procédés de fabrication Ceased WO2008130630A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92383007P 2007-04-16 2007-04-16
US60/923,830 2007-04-16

Publications (3)

Publication Number Publication Date
WO2008130630A2 WO2008130630A2 (fr) 2008-10-30
WO2008130630A3 true WO2008130630A3 (fr) 2009-02-19
WO2008130630A4 WO2008130630A4 (fr) 2009-04-16

Family

ID=39666000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005022 Ceased WO2008130630A2 (fr) 2007-04-16 2008-04-16 Forme polymorphique de l'hydrochlorure de rimonabant et ses procédés de fabrication

Country Status (1)

Country Link
WO (1) WO2008130630A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206182B (zh) * 2011-04-11 2013-03-13 中国药科大学 盐酸利莫那班的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087732A1 (fr) * 2005-01-06 2006-08-24 Cadila Healthcare Limited Forme amorphe et trois formes cristallines de chlorhydrate de rimonabant
WO2008000418A2 (fr) * 2006-06-27 2008-01-03 Sandoz Ag Nouveau procédé de préparation de sel
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087732A1 (fr) * 2005-01-06 2006-08-24 Cadila Healthcare Limited Forme amorphe et trois formes cristallines de chlorhydrate de rimonabant
WO2008000418A2 (fr) * 2006-06-27 2008-01-03 Sandoz Ag Nouveau procédé de préparation de sel
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"RIMONABANT HYDROCHLORIDE ANTIOBESITY DRUG AID TO SMOKING CESSATION TREATMENT OF ALCOHOL DEPENDENCY CANNABINOID CB1 ANTAGONIST", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 30, no. 2, 1 January 2005 (2005-01-01), pages 128 - 137, XP008059586, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
WO2008130630A4 (fr) 2009-04-16
WO2008130630A2 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2008092954A3 (fr) Formes polymorphes d'un inhibiteur macrocyclique de hcv
IL173959A0 (en) ?? crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2009006590A3 (fr) Procédés de préparation de docétaxel et de polymorphes
SG131857A1 (en) δD-CRYSTALLINE FORM OF IV ABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
WO2010067374A3 (fr) Polymorphes de dasatinib
WO2009053854A3 (fr) Polymorphes de dasatinib et leur procédé de préparation
WO2008013838A3 (fr) Dérivés de pyridizinone
EP2460797A3 (fr) Procédé de préparation d'ivabradine hydrochloride
WO2009062044A3 (fr) Procédés de préparation de prasugrel et ses sels et polymorphes
WO2008096001A8 (fr) Phénylcarbamates macrocycliques inhibant le virus de l'hépatite c (vhc)
WO2012070062A3 (fr) Nouveau polymorphe de chlorhydrate de nilotinib
WO2009025873A3 (fr) Procédés pour la préparation de formes cristallines a, b et d'une forme a cristalline pure de chlorhydrate d'erlotinib
WO2008068625A3 (fr) Procédé de fabrication du chlorhydrate de cinacalcet et formes polymorphes de celui-ci
WO2010070449A3 (fr) Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2010129636A3 (fr) Lénalidomide polymorphe
WO2007098273A3 (fr) Nouvelles formes cristallines d'armodafinil et leur preparation
WO2008051564A3 (fr) Formes cristallines d'hydrochlorure de palonosetron
WO2007010555A3 (fr) Nouvelles formes cristallines d'hydrochlorure de moxifloxacine et procede de preparation associe
WO2008034912A3 (fr) Procédé de synthèse du clopidogrel et nouvelles formes de sels pharmaceutiquement acceptables de celui-ci
WO2006081515A3 (fr) Polymorphes d'hydrochlorure de duloxetine
WO2006090268A3 (fr) Procedes de preparation d'alfuzosine et de ses sels, nouvelles formes cristallines d'alfuzosine
WO2009007747A3 (fr) Nouveaux composés
WO2008130630A3 (fr) Forme polymorphique de l'hydrochlorure de rimonabant et ses procédés de fabrication

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009511270

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743058

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08743058

Country of ref document: EP

Kind code of ref document: A2